LyrArc Article Gist
Baucus is a six term senator from Montana. He won easy re-election in the fall. Question are being raised about the extent of fundraising Baucus is doing even as he is conducting the negotiations for writing up the health care reform bill. He continues to accept donations from health care executives and health care companies. Public Citizen advocacy group says that Baucus's fundraising in the middle of the health care debate is very troubling. As chairman of the Senate Finance Committee, Baucus is a key person in the health care legislation development.The Washington Post says health care companies gave Baucus $1.5 million in 2007 and 2008 as he began to hold hearings for the health care reform debate. The health care industry gave $170 million to federal lawmakers in 2007 and 2008, with 54% going to Democrats, according to the Center for Responsive Politics. Senator Grassley of Iowa, the ranking Republican in Baucus's committee received more than $2 million from the health care industry since 2003. House Ways and Means Committee chairman Rangel took in $1.6 million, and ranking Republican Dave Camp $1 million. Clearly any new health care legislation will fall short on achieving the critical reduction in health care costs that is needed to help the U.S. economy as long as lawmakers are beholden to lobbyists and donations....

LyrArc Article Gist
Companies have to work hard to retainthe best young people and the best employees as good talent is scarce in India.

LyrArc Article Gist
Peter Orszag's role in the healthcare debate and the formulation of health care policy proposals. One proposal of Orszag, who heads the Congressional Budget Office, is to set up a new agency with powers to cut spending and implement changes in Medicare. Says Orszag, "one of the reasons we have such disjointed and skewed incentives is that we have an excessively political process." At a recent meeting with House Democrats, one Congresswoman said her top priority is winning higher payments for oxygen suppliers, and Orszag was taken aback. For years officials have been trying to cut payments to oxygen and medical equipment suppliers, which are said to be inflated. When a new competitive bidding process was set to take effect last year, industry supporters in Congress were able to delay the plan, and these supporters are still fighting to block changes says the WSJ. Here is a 40 year old Orszag, with degrees from Princeton and London School of Economics, who got his early experience in the Clinton adminstration at age 24. He then followed this with a number of policy oriented jobs, ending with appointment to head CBO in 2007. And he faces the whole system of Congressmen from both parties beholden to interests in the healthcare industry, who provide the donations for them to finance their election campaigns. Dan Eggen describes this in the Washington Post, 7/21/2009. Max Baucus of Montana, and to some extent Grassley of Iowa, are senators from both parties who Eggen points out are beholden to the healthcare industry because of large donations they receive from the interests in the healthcare industry. These interests want to see their payments system protected. The further escalation in health care costs, which would make the whole healthcare system unaffordable even as it delivers poor results, can only be prevented by making cost control an exercize that is not influenced by healthcare industry donations. Jackie Calmes describes the huge hurdles in achieving a deficit neutral move to universal health care in the U.S. in the NYT 6/26/2009. See the link. The exchange between Grassley and Orszag on the issue of the $177 billion in savings needed from the payments to health insurers under the Medicare managed care plans- which allow seniors to obtain Medicare coverage outside the government run program -went as follows. These are dubbed overpayments by outside experts and efforts have been made to cut them in Congress. When Mr Grassley raised concerns about the impact of such cuts in a hearing, -and Grassley has opposed the cut for this overpayment to insurers- Orszag responded saying: "I very firmly believe that capitalism is not founded on excessively high subsidies to private firms. This is what this system delivers right now." ...

LyrArc Article Gist
An indication of how much controversy is becoming part of the drug risk appraisal process, involving the medical journals, the FDA, the Congress, the drug companies, the courts, and independent physicians, and the users of the drugs, with charges thrown back and forth. The information on Avandia comes from Merck's own website and was an attempt to provide more public disclosure of drug studies conducted by the manufacturer.

LyrArc Article Gist
Sanofi-Aventis and liver risks of its drug Ketek. And the questionable practices of Sanofi in the study assessing the liver risk that the FDA draws attention to in its letter to Sanofi-Aventis.

LyrArc Article Gist
Chinese plant not inspected by the FDA made an active ingredient in a blood thinner for Baxter International. The blood thinner led to 4 deaths. Baxter has temporarily stopped production of its version of Heparin. China has 14% of the $31 billion market for active drug ingredients according to a 2007 report from Credit Suisse. Only 7% of foreign drug making facitlites are inspected each year by the FDA, so its way behind in inspection, and at this rate it would take 13 years to cover all the foreign plants.

LyrArc Article Gist
Only after the FDA made it apparent that it would take atougher stand against taranabant did Merck decide on scrapping this obesity drug which has psychiatric side effects.

LyrArc Article Gist
The FDA has found deficiencies and violations of safe manufacturing practices at 2 Ranbaxy plants in India. The FDA issued a ban on imports of 30 generic drugs from Ranbaxy in India.